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Abstract
Ileal epithelial cell apoptosis and the local microbiota modulate the effects of oxaliplatin against proximal colon cancer
by modulating tumor immunosurveillance. Here, we identified an ileal immune profile associated with the prognosis of
colon cancer and responses to chemotherapy. The whole immune ileal transcriptome was upregulated in poor-prognosis
patients with proximal colon cancer, while the colonic immunity of healthy and neoplastic areas was downregulated
(except for the Th17 fingerprint) in such patients. Similar observations were made across experimental models of
implanted and spontaneous murine colon cancer, showing a relationship between carcinogenesis and ileal inflammation.
Conversely, oxaliplatin-based chemotherapy could restore a favorable, attenuated ileal immune fingerprint in responders.
These results suggest that chemotherapy inversely shapes the immune profile of the ileum–tumor axis, influencing clinical
outcome.
Introduction
The field of cancer treatment has seen major advancements
over the last few years with the approval of immune
checkpoint inhibitors (ICI) for multiple indications.
However, ICIs do not benefit all patients; there are still
major challenges to overcome primary or secondary resis-
tance against immunotherapy. For colorectal cancer (CRC),
microsatellite stability (MSS) is resistant to ICI and repre-
sents the vast majority of CRC [1]. Combination che-
motherapy based on the use of 5-fluorouracil (5-FU) plus
oxaliplatin (OXA) (FOLFOX) is routinely used as first-line
treatment for advanced CRC [2], although with no curative
intention. Therefore, it is important to improve treatment
efficacy by combining standard chemotherapy with ICI. To
do so, the identification of new therapeutic options and
associated biomarkers will help selecting patients for clin-
ical trials and evaluating therapeutic responses.
Recently, the interaction between the gut-associated
immune system (GALT) and the immune tumor micro-
environment (TME) has been recognized. Evidence from
preclinical models and patients unraveled the gut microbiota
and local immunity as a crucial crossroad in the modulation
of responses to cancer therapies (reviewed in ref. [3]). The
gut immune response is the result of a fine-tuned homeo-
static equilibrium between immunity to pathogenic antigens
and tolerance to nonpathogenic ones. Interactions between
the microbiota, the intestinal epithelial barrier, and GALT
continuously shape the function of the gut immune system
[4]. Chemotherapy can affect the integrity of the gut
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epithelial barrier, thus altering the outcome of the local and
systemic immune response.
Our group provided mechanistic insights into how the
microbiota and apoptosis of intestinal epithelial cell (IEC)
in the ileum elicit an immune response against proximal
colon cancer (pCC) in the context of OXA-based che-
motherapy [5]. The local priming of immune cells in the
mesenteric lymph nodes (mLN) culminated in the enrich-
ment of CD3+ T cells, CD8+ cytotoxic T lymphocytes
(CTL), and T follicular helper (Tfh) in the TME, indicating
a favorable immune contexture [6, 7] associated with good
prognosis and treatment response [8]. Whether and how the
local mucosal immune profile was impacted remained
unexplored. In the present study, we describe ileal mucosal
immune changes in pCC patients and their association to
clinical outcome. Furthermore, we demonstrate cause–effect
relationships among the different factors involved in shap-
ing ileal immunity using relevant experimental mouse
models of colon cancer.
We reveal that favorable tumor immunity and clinical
outcome are associated with a relative loss of immune
markers in the ileum. Using spontaneous and transplan-
table colon cancer mouse models, we identified functional
links among tumor, intestinal microbes, and chemother-
apy impacting on ileal immunity, resulting in apparently
opposite changes between ileal inflammation and tumor
immunosurveillance. We believe that these findings are
important for the future development of new treatment
combinations against colon cancers.
Results
Ileal immune parameters dictate pCC patients’
prognosis
We recently provided insights into how ileal IEC death and
the local microbiota elicit a systemic immune response
against pCC during OXA-based chemotherapy [5]. Indeed,
we showed that Tfh primed in the mLNs post OXA accu-
mulates in colonic tumor beds instead of being redirected
toward the chemotherapy-inflamed ileum. In these pCC
patients, we analyzed the ileal immune tonus and its impact
on patient survival.
Right hemicolectomy is the standard surgical treatment
for malignant neoplasms of the right colon, which involves
the resection of the tumor along with nonmalignant tissues,
including the terminal ileum. This procedure allowed us to
concomitantly monitor the ileal and tumoral immune para-
meters, the ileal and colonic microbiota lining healthy tis-
sues, and pCC patient prognosis.
Immunofluorescence-based staining of T-cell subsets in
the ilea and tumor beds revealed an inverse correlation
between CD3+ and CD4+ T lymphocytes within the ileal
epithelium (EP) or lamina propria (LP), and CD8+ tumor-
infiltrating lymphocytes (TILs) in the invasive margins of
the resected pCC (Fig. 1A, B). Hence, cancer T-cell infil-
tration (a surrogate marker of prognosis in CRC) [9] is
particularly dense in patients whose ilea contain few T cells.
Notably, ileal LP Tfh cells exhibited robust anticorrelations
with TILs, including tumor-infiltrating Tfh cells (Fig. 1B).
We next evaluated T lymphocyte-related gene expression
patterns, focusing on a custom panel comprising 15 tran-
scription factors and cytokine genes, by means of quanti-
tative real-time polymerase chain reaction (RT-qPCR)
performed on the terminal ileum and proximal colon seg-
ments removed during surgery. This RT-qPCR reaction was
validated by protein expression for selected gene products,
such as for the aryl hydrocarbon receptor (AHR) for which
gene and protein expressions markedly correlated among
each other (Supplementary Fig. S1A, B). Nonsupervised
hierarchical clustering of immune gene products yielded
two opposite clusters of patient samples, based on the
geodistribution of gene expression, i.e., cluster 1 in which
the mRNAs were scarcely expressed in the ileum but highly
expressed in the colon, and cluster 2 in which mRNAs
exhibited an opposite pattern with high expression in the
ileum and low expression in the colon (Fig. 1C, D). Indeed,
CD3E, TBX21, FOXP3, IL10, GATA3, and IL23A were
more expressed in the colon while being less expressed in
the ileum in cluster 1 compared with cluster 2 (Supple-
mentary Fig. S2, right and left panels). Importantly, these
gene expression profiles had a clinical relevance in thus far
that cluster 1 patients exhibited a prolonged time to treat-
ment failure (progression or cancer-related death) than those
individuals whose ileal signature fell into cluster 2 (Fig. 1E,
clinical characteristics of the patients are detailed in
Table S1, adjusted P values in Table S2). Importantly, ileal
immune gene expression was independent of the disease
stage, and ileal immune tonus even predicted survival of
stage IV pCC metastatic patients (Fig. 1F).
Altogether, we conclude that the immune tonus of the
ileal mucosa correlates with colon cancer immuno-
surveillance, as well as with patient survival.
Colon cancer promotes high ileal immune gene
expression
Although the ileal immune tonus was independent of
tumor stage (Fig. 1C, F), genes coding for CD4, the Tfh-
relevant transcription factor BCL6, the T helper 1-relevant
transcription factor TBX21, and AHR were significantly
(>2-fold) increased in the ileum (Fig. 2A, left panel) but
not in the colon (Fig. 2A, right panel) in more advanced
pCC stages (III/IV) compared with early stages of colon
carcinogenesis.
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Intrigued by these findings, we turned to mouse models to
validate the observation that tumor progression could indir-
ectly stimulate ileal inflammation/immunity. IEC-specific
transgenic expression of the epithelial–mesenchymal transi-
tion regulator Zeb2 in mice (Zeb2IEC-Tg/+ mice) leads to
increased intestinal permeability and spontaneous invasive
colon carcinoma development in a microbiota-dependent
manner [10]. At a young age, Zeb2IEC-Tg/+ mice develop
dysplasia of the colon EP that progresses to neoplastic lesions
[10], but maintain a normal small intestinal EP. Histological
Fig. 1 Ileal immune parameters dictate pCC patients’ prognosis. A
Representative micrographs of (top panel) CD8+ T-cell infiltrates in
the tumor core by immunohistochemistry (IHC) with delineation of
tumor areas by dotted black lines and (bottom panel) CD3+ and CD4+
T-cell infiltrates by immunofluorescence (IF) staining in autologous
ilea of two distinct pCC patients. Scale bar= 100 µm. B Heatmap
showing Spearman correlation coefficients between autologous tumor
and ileum immune cell densities in 53 distinct pCC patients for whom
paired samples were available. *P < 0.05. IEL intra-epithelial lym-
phocytes, LP lamina propria, CT core of the tumor, IM tumor invasive
margin. C Dendrogram and heatmap depicting the agglomerative
hierarchical clustering of pCC patients (n= 83, columns) according to
ileal and colonic immune gene transcription (rows) at surgery. Dis-
tance was measured with 1–Pearson correlation coefficient and
agglomeration with Ward’s method. Clinical variables and tissue of
origin are indicted by the corresponding color code on the top and side
border, respectively. D Heatmap of gene expression patterns in auto-
logous ileum and colon as a log2 fold ratio (FR) between cluster 1 and
cluster 2 individuals. Mann–Whitney U test: *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001. E, F Kaplan–Meier curves for time to
treatment failure (progression or cancer-related death) segregated
according to the clustering from (C) analyzed by Mantel–Cox
regression test in 83 pCC patients (E) or only in stage IV metastatic
pCC patients (F).
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examination of colon tissues revealed different grades of
tumor progression in individual mice. Among mucinous
tumors in the proximal region of the colon, we observed
cancers with clear signs of transmural invasion and
growth throughout the muscularis mucosae until peritoneum
invasion (Fig. 2B). The presence of invasive tumors in
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Zeb2IEC-Tg/+ mice was associated with increased expression
of ileal immune genes (such as Cd3e, Cd4, Ahr, Rorc, Bcl6,
Gata3, Il10, Il23a, and Il27) compared to Zeb2IEC–+/+ wild-
type (WT) littermates (Fig. 2C, Supplementary Fig. S3A and
Table S3). RT-qPCR examination of these tumor areas
revealed a positive correlation between tumor burden and
several immune genes found in ilea from pCC patients, such
as Cd4, Bcl6, and Gata3 (Supplementary Fig. S3B).
We next investigated whether shifts in the gut microbiota
might explain these ileal alterations during the colon car-
cinogenesis program. Of note, rederivation of Zeb2IEC-Tg/+
mice in germ-free (GF) conditions completely abrogated
cancer development [10]. Mice reared in specific pathogen-
free (SPF) conditions exhibited a more pronounced Th1/
Treg profile and an attenuated Il-17 tonus in their ilea as
compared to axenic Zeb2IEC-Tg/+ (Supplementary Fig. S3C).
However, during colon carcinogenesis, ilea from SPF
Zeb2IEC-Tg/+ still manifested a relative overexpression in
Il10, Gata3, and Il27 genes (Supplementary Fig. S3C and
Table S4), suggesting that this ileal immunomodulation did
not depend on the ileal microbiome.
To validate the notion that cancer can induce ileal
inflammation, we switched to a transplantable colon tumor
model that can be inoculated subcutaneously (s.c.) into
syngeneic immunocompetent mice. We compared the ileal
immune transcriptome of mice bearing s.c. MC38 cancers
with that of naive tumor-free mice. Here again, we con-
firmed that the ileal mRNAs encoding Gata3, Bcl6, Rorc,
and Tbx21 were increased in tumor bearers at day 10 of
implantation compared to naive counterparts. In contrast,
Cd4, Foxp3, and Il10 transcription were reduced in the
colon (Fig. 2D).
These results indicate that the presence of colon carci-
nogenesis is accompanied by a higher ileal immune tonus,
paralleling tumor progression in human and mice.
Chemotherapy alters the cancer-induced ileal
immune activation
The GALT provides specific types of immune responses
to local challenges along the gastrointestinal tract. We
recently showed that the ileal crypt cells were the main
targets of OXA-based chemotherapy with respect to
apoptosis induction [5]. Driven by this observation, we
evaluated the impact of systemic cytotoxicants on the ileal
immune signature.
Given that FOLFOX is the first-line standard chemother-
apy for most patients with advanced CRC [2], we adapted this
treatment to the mouse model, treating Zeb2IEC-Tg/+ mice with
a mixture of 5-FU and OXA. Histological examination of the
colons and quantification of tumor invasion (as in Fig. 2B)
revealed a mild response to therapy compared to PBS-treated
controls (Fig. 3A), as expected given the aggressiveness of
this model [10]. However, we did observe a chemotherapy-
induced immune response in the TME with a significant
increase in CD8+ cells, though no alteration in the frequency
of CD3+ T cells (Fig. 3B, C). We found a negative correlation
between the expression of ileal immune genes and the fre-
quency of CD8+ TILs only in chemotherapy-treated mice
(Fig. 3D), suggesting that chemotherapy partially dampened
the ileal immune signature (Cd4, Tbx21, Il10, and Il27)
associated with carcinogenesis (Fig. 3E).
In conclusion, tumor infiltration showed a negative
correlation with ileal immune tonus after chemotherapy
in an aggressive spontaneous mouse model of colonic
carcinogenesis.
Bacteria regulate the antitumor efficacy of OXA by
shaping the ileal immune profile
Ileal apoptosis may affect the composition of the ileal
microbiota and therefore influence immune responses in the
GALT and tumor beds [5]. Therefore, we evaluated the
fecal and ileal microbiota of our cohort of pCC patients [5].
An abnormal (or “dysbiotic”) fecal microbial repertoire has
been detected during adenoma–carcinoma transformation
[10] as well as in CRC patients [11–13]. We performed 16 S
rRNA gene sequencing of gene amplicons of ileal mucus
from our previously described [5] pCC cohort (n= 70).
Volcano plots revealed an overabundance of Prevotellaceae
family members in ileal samples from patients diagnosed
at advanced pCC stages (i.e., Prevotella buccalis and
Prevotella denticola) compared with earlier stages (Sup-
plementary Fig. S4). We next examined the ileal immune
signature in relation to the ileal microbiome assessed by
Fig. 2 Inverse relationship between ileal and cancer immune tonus
in CC models. A Volcano plots of the differential immune gene
transcription in qPCR of ileum (A) and colon (B) mucosae contrasting
stage I–II versus stage III–IV pCC patients (TNM staging system).
Volcano plots were generated computing for each gene product
expressed in intestinal mucosae of 83 pCC patients: (i) the log2 of fold
change (FC) among the mean relative abundances of transcripts after
normalization in early versus advanced disease stages (x axis); (ii) the
co-log10 of P values deriving from Mann–Whitney U test calculated on
relative abundances in absolute values (y axis). Green and gray dots
are considered significant (P < 0.062) or not (P > 0.062), respectively.
B Representative micrographs of hematoxylin and eosin (H&E)-
stained sections of intestinal samples collected from Zeb2IEC-Tg/+ mice
showing different tumor progression. Scale bar: 50 µm. C Relative
expression of immune genes in ilea of Zeb2IEC-Tg/+ mice and WT
littermates as assessed by RT-qPCR. One dot represents one ileum and
the pooled data of all ilea are shown. Mean ± SEM are depicted.
Mann–Whitney U test P values are shown. D Relative expression of
immune genes in ilea and colon of MC38-bearing mice WT versus
naive WT mice as assessed by RT-qPCR. One dot represents
one ileum or one colon and the pooled data of all ilea or colons are
shown. Mean ± SEM are depicted. Mann–Whitney U test P values
are shown.
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16S rRNA gene sequencing of the same patients. Surpris-
ingly, the ileal microbiota could segregate patients classified
according to their ileal immune gene expression. At the
level of bacterial families or classes, Volcano plots
highlighted an overabundance of the Erysipelotrichaceae
family and the Negativicutes class (such as Acid-
aminococcaceae, Selenomonadales unclass.) in cluster 1
patients (with better prognosis than cluster 2 patients)
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients 1537
(Fig. 4A, left panel). At the species level, there was a sig-
nificant enrichment in Prevotella spp. (P. oralis, P. oryzae)
in cluster 2 patients with dismal prognosis compared to
cluster 1 (Fig. 4A, right panel). Conversely, the only bac-
terium enriched in the favorable cluster 1 (compared with
cluster 2) was Bacteroides fragilis (Fig. 4A, right panel), in
line with the previously reported association of this species
with an immunogenic ileal microbiota [5].
To establish a cause–effect relationship between the
microbiota composition and the ileal prognostic signature,
we took advantage of the “avatar” model in which GF mice
(previously shown to be nonresponders to OXA [14])
received fecal microbiota transplantation (FMT) from
human pCC patients and hence were “humanized” with
respect to a potentially pathogenic intestinal microbiota [5].
In these gut experiments of “humanization”, some patient
feces (8/12 cases) yielded an avatar responder (aR) phe-
notype in the mice, meaning that subsequently implanted
MC38 responded to OXA treatment, while others yielded
an avatar nonresponder phenotype (aNR) [5]. OXA-treated
aR (but not aNR) mice showed a depletion of the mRNAs
coding for Cd4, Tbx21, Rorc, Ahr, Bcl6, and Foxp3 from
their ilea (Fig. 4B). This difference between aR versus aNR
transcriptomes was only found in the ileum, not in the colon
(Fig. 4B and Supplementary Table S5).
Of note, we previously reported that aR mice exhibited
a stronger increase in Tfh cells in tumor- draining lymph
nodes (tdLNs) than aNR mice [5]. The abundancy of Tfh
in tdLN modulated by FMT negatively correlated with the
expression of Bcl6 in the ileal mucosa (Fig. 4C, left
panel), confirming the negative relationship between ileal
and tumor-specific immunity outlined in Fig. 1 in patients.
Conversely, tdLNs from aNR mice contained higher
CCR6+CXCR3– CD4+ Th17 cells (known to be asso-
ciated with an immuno-suppressive milieu [15]) than
those from aR mice, and such cells exhibited a positive
correlation with ileal Ahr mRNA levels, AhR being a
transcription factor associated with Th17 differentiation
[16] (Fig. 4C, right panel).
Ileal immune responses mainly take place in mLNs
where T cells acquire a gut tropism and relocalize within
intestinal EP or LP [17]. However, lymphocytes can
dynamically migrate through the lymphatic space to find a
cognate antigen in other locations, including extraintestinal
tumor sites by various homing mechanisms [18]. To test the
impact of the microbiota in altering migration patterns of
lymphocytes primed in the gut, we performed oral gavages
with bacteria associated with favorable (such as Bacteroides
fragilis) or dismal prognosis (such as Paraprevotella clara).
We administered this oral supplementation twice, 24 hours
before and after OXA i.p. injection. Here again, we found a
mirror image of the leukocyte infiltration induced by orally
administered bacteria in the ileal mucosa and the tumor
bed. B. fragilis was associated with higher TILs and lower
CD45+ cells in the ileal compartment, compared to
P. clara-treated groups (Fig. 4D).
The aforementioned results support the notion that the
ileal microbiota shapes local immune responses, which then
control colon cancer immunosurveillance.
Discussion
Here, we demonstrate that the prognosis of pCC patients is
associated with an ileal immune fingerprint that inversely
correlates with the colonic signature and appears to be
linked to tumor immunosurveillance.
First, we highlighted in a cohort of 83 pCC patients that
those individuals presenting with a low ileal immune gene
transcriptome have a favorable prognosis, even when
diagnosed with a stage IV pCC (Fig. 1C, F). Second, the
CD3+CD4+ T cells of IELs and LP inversely correlated
with CD3+CD8+ counts, a central parameter of the immu-
noscore [7] (Fig. 1B). Indeed, scarce expression of immune
genes in the ileum corresponded to high immune gene
expression in healthy colons, specifically for gene products
of the Th1 (CD4, TBX21), Th2 (GATA3), and Treg
(FOXP3, IL10) differentiation profile, while the Th17 pat-
tern (centered around IL17A, AHR, and RORC) was rela-
tively stable across the small and large parts of the intestine
(Supplementary Fig. 2). This might account for the colon
cancer infiltration of those Th1/Th2 cells in the core of the
tumor in favorable cases.
Conversely, the ileal immune tonus was affected by
colonic carcinogenesis as indicated by the fact that the since
Fig. 3 Ileal immune parameters are restored by OXA-based che-
motherapy. A Assessment of tumor loads by quantification of tumor
areas in in situ, submucosal, muscular, and peritoneal tumors in
Zeb2IEC-Tg/+ mice treated with 5-FU+OXA or vehicle (PBS control).
B Representative micrograph of CD3+ (left panel) and CD8+ (right
panel, indicated with arrows) cell infiltrates by IHC staining in the
tumors of Zeb2IEC-Tg/+ mice treated by 5-FU+OXA or PBS control.
Scale bar: 50 µm. C Quantification of CD3+ (upper panel) and CD8+
(lower panel) cell densities in tumors of Zeb2IEC-Tg/+ mice (relative to
IHC staining in B). Mann–Whitney U test P values are shown.
D Heatmap showing Spearman correlation coefficients between ileum
immune gene expression and CD8+ cell densities in tumors (quantified
in C) of Zeb2IEC-Tg/+ treated by 5-FU+OXA (or PBS control). CD8+
TILs were assessed by IHC and quantified in tumor areas with dif-
ferent degree of invasion. Significant correlations are indicated, *P <
0.05. CIS carcinoma in situ, SM submucosal tumor, IM muscle-
invasive tumor, IP invasive tumor in the peritoneum; Total: total tumor
area. E Spearman correlation between ileum immune genes and CD8+
cell densities in tumor. CD8+ TILs were assessed by IHC and quan-
tified in tumor areas with different degrees of invasion. One dot
represents one mouse; the black and dotted lines show the regression
line and 95% confidence intervals, respectively. Spearman coefficients
and P values are shown in the figures. CIS carcinoma in situ, SM
submucosal tumor, IP invasive tumor in the peritoneum.
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growth of heterotopic (s.c. MC38) or orthotopic (EMT-
induced Zeb2-transgenic) colon cancers induced this upre-
gulation of ileal immune gene products (Fig. 2C, D). At this
point, it remains an open question how tumors can send
proinflammatory signals to the ileum.
We also found evidence that OXA-based chemotherapy
reshuffles the ileal immune system, favoring the reduction
of immune transcription of a variety of gene products in
MC38-bearing avatar mice as well as in Zeb2-transgenic
animals (Figs. 3 and 4). The striking negative correlations
found in the Zeb2IEC-Tg/+ and s.c. MC38-transplantable
models between the ileal and tumor immunity post-OXA-
based therapy suggest that antigen-specific T cells could be
primed in mLNs and migrate back to tumor beds instead of
returning to the inflamed ileal mucosa. Although spec-
ulative, this is in line with our previous findings obtained in
s.c. MC38 in which OXA generated an immunogenic cell
death of ileal IEC that contributed to elicit Tfh in mLNs
and tdLNs and fosters CD8+ T-cell-dependent tumor con-
trol [5]. We reported that OXA treatment triggered the
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migration of ileal CD11b–CD103+ LP-DCs to the mLN and
their upregulation of IL-12 and IL-1β in a gut microbiota-
dependent manner [5]. We also reported that migratory LP-
DCs from the terminal ileum contributed to Tfh priming
post OXA [5]. It is tempting to speculate that T cells primed
in mLN may either traffic back to the ileal inflammation
caused by OXA-induced apoptosis of the crypts or instead
are redirected to tumor lesions. It is conceivable that the
chemokine axis is reshuffled by cytotoxic agents in both
ileal and tumor epithelia in an inversed manner, changing
the homing equilibrium between gut to tumor beds, as
previously shown for CCR9+ T cells [19, 20].
Functional links between ER stress in the epithelial
barrier and immune activation in the TME were recently
reported in Rnf5−/− mice [21]. RNF5 is a membrane-
anchored E3 ubiquitin ligase implicated in endoplasmic
reticulum (ER)-associated protein degradation. Decreased
secretion of antimicrobial peptides and increased cell death
in the ileal crypts caused intestinal dysbiosis in Rnf5−/−
mice. This bowel injury allowed the recruitment, activation,
and mobilization of CCR7-expressing dendritic cells to
Peyer patches, mLN [22], and tdLN, culminating in the
massive infiltration of IFNγ-producing CD4+ and CD8+
TILs and tumor control of poorly immunogenic melanoma
[21]. The microbiota shift in Rnf5−/− mice was underscored
as a key factor in the immunosurveillance mechanisms. This
report is in line with our findings showing that some
intestinal commensals can affect the ileal immune system
during OXA-induced cancer immunosurveillance. By seg-
regating responders from nonresponders in “humanized”
mice bearing colon cancers, we demonstrated that the OXA-
induced reduction of tumor size was associated with low
ileal immune transcription (Fig. 4B, C), paralleling Tfh
accumulation and Th17 reduction in tdLNs in responders.
Patients diagnosed with pCC belonging to cluster 1 (dis-
playing a low ileal immune profile, Fig. 1C, D) presented a
relative dominance of B. fragilis and an underrepresentation
of Prevotella spp., these two species creating an opposite
balance of the leukocyte infiltrates in the ileum and tumors
(Fig. 4D). In our previous work [5], we showed that B.
fragilis contributes to IL-12- and IL-1β-dependent priming
of Tfh in tdLNs. Other reports proposed alternative
mechanisms on how microbial species could modulate
T-cell patrolling patterns during carcinogenesis. Microbial
species may induce a burst of chemokines in GALT or in
the TME, thus affecting the trafficking of helper and
effector T cells [21]. In CRC, the commensals may act on
cancer cells to modulate their capacity to produce chemo-
kines that may govern the immunoscore and patient prog-
nosis through the recruitment of Th1, Tfh, or Th17 cells into
the tumor bed [23]. In hepatocellular carcinoma, the gut
microbiome uses bile acids as messengers to regulate che-
mokine CXCL16 levels on liver sinusoidal endothelial cells
in order to control the accumulation of CXCR6+ hepatic
natural killer T (NKT) cells that keep liver tumors at bay
[24]. In contrast, lipoteichoic acid, a cell wall component of
Gram-positive bacteria, enhances the senescence-associated
secretory phenotype of hepatic stellate cells in collaboration
with a gut microbial metabolite, deoxycholic acid, and
upregulates the inflammatory cascade and COX2 in a
TLR2-dependent manner. In turn, COX2-mediated pros-
taglandin E2 production suppresses the antitumor immu-
nity, thereby contributing to hepatocellular carcinoma
progression [25].
Previous reports using oral administration of anticancer
probiotics analyzed the immunomodulatory effects of these
live biotherapeutics on the colonic mucosae, highlighting
the accumulation of IFNγ-producing CD8+ T cells as a
surrogate marker of tumor immunosurveillance of cancers
established in gut or extraintestinal locations. Tanoue et al.
used a 11-strain-based product that elicited potent cytotoxic
T-cell responses, including tissue-resident T cells devoid of
colitis-inducing properties that were associated with ICI-
induced anticancer effects against melanoma [26]. Wang
et al. administered Akkermansia muciniphila and its bac-
terial TLR4 derivative A-muc_1100 that both prevented
colitis-induced CRC and CT26 by inducing the colonic
accumulation of TNFα-producing CD8+ T cells elicited in
mLN and spleens [27]. In these reports, including ours, it is
unclear to which extent these CTL responses elicited from
the gut and redirected to TME contribute to the antitumor
effects. Some of these CTL responses might be specific for
bacterial antigens, sharing some molecular mimicry with
Fig. 4 Microbiome composition regulates the antitumor efficacy of
OXA by shaping ileal immune profile in experimental models.
A Volcano plot representation of differential microbiota composition
at family (A) and species (B) levels matching cluster 1 versus cluster 2
pCC patients as defined in Fig. 1C. Volcano plots were generated
computing for each bacterial family (left) or species (right) residing in
ileal mucosae of 83 pCC patients: (i) the log2 of FR among the mean
relative abundances in cluster 1 versus cluster 2 (x axis); (ii) the co-
log10 of P values deriving from Mann–Whitney U test calculated on
relative abundances (y axis). Green dots are considered significant at
P < 0.05 (gray dots p > 0.05). B. Heatmap of the Log2 FR of the
immune gene transcript levels between aNR and aR wild-type mice in
PBS and OXA-treated groups in ilea and colons at sacrifice (day 21).
Mann–Whitney U test: *P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001. C Spearman correlations between ileal Bcl6 gene transcripts
and percentages of Tfh (left panel) and between ileal Ahr gene tran-
scripts and percentages of CCR6+CXCR3–/CD4+ T cells determined
by FACS in tdLN in OXA-treated avatar groups at sacrifice (day 21
after treatment). The black and dotted lines show the regression line
and 95% of confidence intervals, respectively. Spearman coefficients
and P values are shown in the figures. D Flow cytometry analysis of
CD45+ lymphoid cell infiltration in tumor and ileal epithelial com-
partment of MC38 tumor-bearing mice treated with OXA and gavaged
with B. fragilis or P. clara. Each dot represents one tumor or one ileum
at sacrifice (day 4 after treatment). Means ± SEM are depicted.
Mann–Whitney U test P values are shown.
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tumor epitopes [28, 29] or be directly presented by MHC
class I molecules on tumor cells that were primarily infected
by such bacteria [30, 31]. More work is needed at the TCR
and single-cell level to elucidate the relevance of such TILs
for cancer immunosurveillance.
Regardless of the detailed mechanism defining the ileal
signature, some clinically relevant issues may arise from our
data. First, based on our previous [5] and the present mul-
tidimensional analyses (including microbial composition,
and immune-related gene expression profiles), we surmise
that the ileal mucosa represents the intestinal compartment
that most closely determines the prognosis of advanced
pCC patients (Fig. 5). Given that sidedness has recently
been shown as a major negative prognostic factor in
metastatic CRC [32–34], stratification of stage IV pCCs
based on the ileal immune signature has great potential
for decision-making, regarding adjuvant therapies. A high
preexisting cytotoxic T-cell infiltrate in the TME predis-
poses to sensitivity to ICI [35, 36]. While most biomarkers
relate to the immune contexture of the primary CRC [9], the
present data offer alternative predictors of response to OXA
and its combination with ICI by assessing the ileal
fingerprint (immune gene expression pattern and micro-
biome composition) to address the prognosis of metastatic
patients. This signature can be routinely studied upon pCC
surgery, taking advantage of the systematic resection of the
terminal ileum. Further prospective work is ongoing in our
laboratories to validate these novel biomarkers in MSI
and MSS CRC. In addition, our present and previous [5]
findings strongly advocate for the use of ileum and crypt-
targeting cell death inducers in combination with such
immunotherapies to convert “cold” into “hot” pCCs,
regardless of their MSI status.
Materials and methods
Patients
In a cohort of pCC patients who underwent hemicolectomy,
we previously reported the epithelial and microbial para-
meters that were significantly associated with outcome [5].
The inclusion criteria for the study were patients with colon
adenocarcinoma who underwent right hemicolectomy plus
Fig. 5 The interactive dialog between the microbiota, the immune
system, and the epithelial barrier in the ileal mucosae of colon
cancer patients. Ileal IEC apoptosis together with natural adjuvants
from distinct commensals elicit an immune response against self-
antigens (likely derived from crypt/villus-progenitor cells) that even-
tually infiltrates proximal colon cancers (pCC) as demonstrated in
Roberti et al. [5]. Here we show the relevance of ileal mucosal immune
transcriptome on the prognosis of pCC patients and its connection with
ileal microbiota. In advanced staging or nonresponders to adjuvant
therapies, the whole immune ileal transcriptome remains upregulated,
while immune gene products encoding transcription factors and
cytokines are downregulated in the healthy colon mucosae. This mirror
image between ileum and colon of the inflammation and immunity
fingerprints in the lamina propria and/or epithelial areas may reflect a
coordination of the two compartments to face the challenge of tumor
progression. The empty boxes refer to our previous work reported in
Roberti et al. [5]. The colored boxes and arrows with stars* represent
the follow-up study proposed in this paper.
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ileal resection (last 10 centimeters). The number of samples
was selected based on availability of the samples. Patients
were not on antibiotics at the moment of surgery. Four
different health cancer centers participated in the study:
Gustave Roussy Cancer Campus (Villejuif, France), Centre
G-F Leclerc (Dijon, France), Hôpital Bicêtre (Le Kremlin-
Bicêtre, France), and Centre hospitalier universitaire-
Estaing (Clermont Ferrand, France). Clinical studies were
conducted according to the ethical guidelines and approval
of the local CCPPRB. The study received the legal
authorization by the Ministère de l’Enseignement Supérieur
et de la Recherche (AC-2013-1884). Written informed
consent in accordance with the Declaration of Helsinki was
obtained from all patients.
Patients’ clinical categorization and follow-up
The information pertaining to tumor staging (TNM staging
system of the American Joint Committee on Cancer—
AJCC) and MSI status was obtained in pathology reports.
Information pertaining to cancer recurrence, death, and
causes of death was obtained from hospital records. All
observations were censored at loss to follow-up and at the
end of the study period. OS was measured from the date of
surgery to the date of death from any cause. Time to
treatment failure (TTF) was measured from the date of
surgery to the date of local or regional recurrence, distant
metastases, or death from cancer and treatment-related
death; patients were censored at non-cancer-related death
(TTF study period 1000 days).
Preparation of patients’ samples for the study
Samples were collected at the time of surgery. Fecal content
from colon for FMT experiments and mucus adherent to the
ileum mucosae for 16 S rRNA gene sequencing were
already described [5]. Mucosal biopsies: approximately 4
cm2 of ileal and nontumoral colonic tissue (distant from the
tumor) that included at least the submucosa was removed,
cut into small pieces (approximately 1 cm2), and transferred
in sterile cryotubes. All samples were immediately frozen at
−80 °C after collection. Tumor samples were retrieved from
formalin-fixed paraffin-embedded (FFPE) tissue from the
pathology archives. Paired analyses were done with the
maximal number of available samples; there were no
exclusions, except for samples that did not meet the quality
control criteria. Patients’ clinical characteristics are detailed
in Table S1.
Mice
Female C57BL/6 mice were purchased from Harlan. Mice
were used between 7 and 14 weeks of age. GF C57BL/6
were obtained from the facility located at CDTA (Cryo-
preservation, Distribution, Typage et Archivage, Orléans,
France). Zeb2IEC-Tg/+ mice were previously described [10].
Axenic mice were housed in positive-pressure isolators.
All experiments were performed on mice of C57BL/6
genetic background. Mice were housed in individually
ventilated cages in a SPF animal facility. Experiments were
performed at the animal facility in Gustave Roussy Cancer
Campus, at the VIB Center for Inflammation Research and
the GF facility of Ghent University. All experiments on
mice were performed in compliance with institutional and
European laws and regulations (Ministère de la Recherche,
de l’Enseignement Supérieur et de l’Innovation, MESRI,
and Ethical Committee for Animal Experimentation at
Ghent University’s Faculty of Sciences and Faculty of
Medicine and Health Sciences). Sample sizes were decided
based on previous publications and experience and common
standards in similar field, for calculating statistical sig-
nificance. No animals were excluded from the analysis.
Tumor immune profiling by immunohistochemistry
in human samples
These results were previously reported [5]. In the present
study, we reanalyzed them (n= 53) to perform correlations
with the ileum immunity.
Immunofluorescence staining, scanning, and
analysis for CD3 and CD4 expression in ileum
For multiplexed staining, 3-µm-thick sections of formalin-
fixed, paraffin-embedded ileal tissue were stained by auto-
mated immunostainer (DISCOVERY ULTRA, Ventana,
IGR). Heat-induced antigen retrieval in Citrate buffer (pH
6.0) for 10 minutes at 100 °C was performed. Then, the
slides were incubated on primary monoclonal rabbit anti-
human CD4 antibody (Spring, SP35, 0.5 µg/mL) for 1 hour
at 37 °C, detected by Discovery UltraMap anti-rabbit HRP
(Ventana, #760-4315), and visualized by Discovery Cy5 kit
(Ventana, #760-238). Heating step with Citrate Buffer was
carried out, as described above. Next, the slides were
incubated on primary polyclonal Rabbit anti-human CD3
antibody (DAKO, #A0452, 3 µg/mL) for 1 h at 37 °C,
detected by Discovery UltraMap anti-rabbit HRP (Ventana,
# 760-4315), and visualized by Discovery FAM kit (Ven-
tana, # 760-243). After the heating step with Citrate Buffer,
nuclei were subsequently visualized with Spectral DAPI
(Perkin Elmer, FP1490, 1:10). Fluorescence analysis. Ima-
ges displayed in the figures were acquired as whole-slide
images (WSI) with a slide scanner Zeiss Axio Scan.Z1
(objective Plan-Apochromat 20×/0.8, 3CCD camera Hitachi
HV-F202SCL) and exported from the Zeiss Zen 2 lite
software as TIFF images. Some of the WSI were processed
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with using an algorithm developed in Visiopharm Integrator
System (VIS) (Visiopharm A/S, Denmark). ROI was
defined for each WSI by applying a threshold on the DAPI
intensity, and then mean fluorescence intensity was mea-
sured in those ROIs.
Characterization of gut immune gene expression
profile by real-time quantitative PCR analysis
Total RNA from gut biopsies was extracted with RNeasy
Mini Kit (Qiagen) and then reverse-transcribed into cDNA
with the SuperScript III Reverse Transcriptase and the RNa-
seOUT™ Recombinant Ribonuclease Inhibitor (Life Tech-
nologies, Saint Aubin, France), in the presence of random
primers (Promega, Charbonnieres, France) and the Deox-
ynucleoside Triphosphate Set, PCR grade (Roche Diag-
nostics, Meylan, France). cDNA was analyzed by real-time
quantitative PCR (RT-qPCR) with the TaqMan method with
TaqMan® Gene Expression Assays using the Universal
Master Mix II (Invitrogen) according to the manufacturer’s
instructions using the 7500 Fast Real-Time PCR system
(Applied Biosystems). Expression was normalized to the
expression of the housekeeping gene of Beta 2 Microglobulin
by means of the 2−ΔCt method. All primers were from Taq-
Man® Gene Expression Assay (Thermo Fisher).
Mouse primers: B2m (Mm00437762_m1), Cd3e
(Mm01179194_m1), Cd4 (Mm00442754_m1), Tbx21
(Mm00450960_m1), Ifng (Mm01168134_m1), Rorc
(Mm01261022_m1), Il17a (Mm00439618_m1), Foxp3
(Mm00475162_m1), Il10 (Mm01288386_m1), Gata3
(Mm00484683_m1), Il27 (Mm00461162_m1), Il23a
(Mm00518984_m1), Bcl6 (Mm00477633_m1), Ahr
(Mm00478932_m1), Fos (Mm00487425_m1), and Jun
(Mm00495062_s1).
For studies comparing naive mice to MC38-bearing WT
mice: MC38 bearers bearing WT mice n= 21 and naive
WT n= 6 mice have been tested.
For studies comparing WT mice (littermate controls) to
Zeb2IEC-Tg/+ n= 16 samples from WT mice and n=
5 samples from Zeb2IEC-Tg/+ have been tested.
For studies comparing GF mice to SPF mice, WT SPF
mice n= 16, WT GF mice n= 7, Zeb2IEC-Tg/+ SPF mice n=
5, and Zeb2IEC-Tg/+ GF mice n= 9 have been tested.
For studies characterizing gut immune gene expression
profile in different tumor locations, nontreated Zeb2IEC-Tg/+
mice n= 6 and treated Zeb2IEC-Tg/+ mice n= 12 have been
tested.
Human primers: B2M Forward: 5′-GATGAGTATGCCT
GCCGTGT-3′; B2M Reverse 5′-AATTCATCCAATCCAA
ATGCG-3′; B2M Probe 5′-(6FAM) AACCATGTGACTTT
GTCACAGCCCAA(TAM)-3′, CD3E (Hs01062241_m1),
CD4 (Hs01058407_m1), TBX21 (Hs00894392_m1), IFNG
(Hs00989291_m1), RORC (Hs01076112_m1), IL17A
(Hs00174383_m1), FOXP3 (Hs01085834_m1), IL10
(Hs00961622_m1), GATA3 (Hs00231122_m1), IL27
(Hs00377366_m1), IL23A (Hs00372324_m1), BCL6
(Hs00153368_m1), AHR (Hs00169233_m1), FOS
(Hs04194186_s1), JUN (Hs01103582_s1). A total of n=
83 patients have been tested.
Analyses were done with the maximal number of avail-
able samples; there were no exclusions, except for samples
that did not meet the quality control criteria.
Chemotherapeutic treatment of Zeb2-transgenic
mice
All chemotherapies were obtained from the Gustave Roussy
Cancer Campus. Mice were allocated to groups ensuring an
equal distribution of genders. When mice were 6 weeks old,
5-FU and OXA were administered i.p. at 50 mg/kg and
10 mg/kg, respectively. A second treatment with OXA was
performed at week 10 with the same dose (n= 12). Mice
from control groups were injected with PBS (n= 6). Mice
were euthanized at week 15 to examine drug effects. One
experiment was performed for IHC analysis and two inde-
pendent experiments were performed to analyze ileal gene
expression (one comprising GF Zeb2-transgenic mice).
Tumor immune profiling by immunohistochemistry
in the Zeb2-transgenic model
Immunohistochemistry staining, scanning, and analysis of
double-staining CD8–CD3. Rabbit anti-mouse CD8α mono-
clonal Ab (Cell signaling, #D4W2Z, 1:400) and rabbit anti-
mouse CD3 polyclonal Ab (Dako, #IS503) were performed
on 3-µm-thick sections of formalin-fixed, paraffin-embedded
colon from murine samples (nontreated mice, n= 6, and
treated mice, n= 12). Antigen retrieval was performed by
incubating slides in Tris-EDTA (pH 8.0) for 30min at 98 °C.
Then the antibodies were successively incubated for 1 h for
CD8 and CD3 at room temperature, and detected respectively
by PowerVision poly HRP anti-rabbit IgG (MM France,
#PV6119). These slides were revealed by DiAminoBenzidine
(DAKO, #K3468). Finally, the sections are counterstained by
Hematoxylin (RAL Diagnostics, #3205501000). Images dis-
played in the figures were acquired as WSIs with a slide
scanner Olympus VS120 at 20× objectives. For mouse tissue
analysis, QuPath software was used [37]. Regions of interest
(ROIs) of normal tissue or tumor were defined by two
pathologists (SY and PO). CD3+ or CD8+ cells were iden-
tified using QuPath software.
FMT experiments
Tumor growth and FACS analysis of tdLN were reported
before [5].
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Subcutaneous model of MC38 for therapy settings
MC38 cell line was derived from methylcholanthrene-induced
murine colon adenocarcinoma cells (NCI, Bethesda, MD) and
tested negative for mycoplasma contamination. Syngeneic
C57BL/6J mice were implanted with 1 × 106 MC38 WT cells
s.c. and treated i.p. when tumors reached 20–30mm2 in size
with 10 mg/kg OXA or vehicle (PBS). Mice of the same age
and gender were randomly allocated in the different experi-
mental groups, ensuring an equal distribution of tumor sizes
for therapeutic experiments.
Gut colonization with dedicated species
The tested species, Bacteroides fragilis and Paraprevotella
clara, were isolated by culturomics from ileum samples
from a previous study [5]. Species were grown on 5% sheep
blood-enriched Columbia agar (bioMerieux) in an anaerobic
atmosphere created using anaerobic generators (bioMer-
ieux) at 37 °C for 24–72 h. Colonization of MC38-bearing
SPF mice was performed by oral gavage with each species
(n= 6 mice per group). For bacterial gavage, colonies were
resuspended in PBS at a concentration of 109 CFU/mL,
evaluated using a fluorescence spectrophotometer (Eppen-
dorf) at an optical density of 1 measured at a wavelength of
600 nm. Two bacterial gavages were performed for each
mouse, the first, 24 h before the treatment with OXA and
then 24 h after the treatment.
Flow cytometry analyses
Tumors and ileal cells were harvested at the end of the
experiment for immunological analysis. Gut dissociation to
harvest cells from the epithelial compartment was per-
formed as previously described [38]. Briefly, ilea and/or
colons were collected and fat tissue, Peyer’s patches, and
feces were removed. Intestines were cut longitudinally and
then cut transversally into small pieces into a tube. Pieces
were transferred into a new 50-mL tube with 20 mL of
dissociation medium (PBS, 5% FCS, 5 mM EDTA, and 1
mM DTT), vortexed, and shaken at 37 °C for 15 min. Cell
suspensions were collected in a new tube, filtered with a cell
strainer (100 μm), centrifuged, and resuspended in PBS.
The dissociation steps were performed twice and cell sus-
pensions stored on ice until use. For tumor dissociation,
tumors were cut into pieces of 2-mm side in RPMI medium,
digested with Liberase™ TM (Sigma) and DNAse I
(Roche) for 30 min at 37 °C. Subsequently, the cells were
meshed through a 100-μm cell strainer to retrieve single-
cell suspensions. In all cases, two million cells were
preincubated with purified anti-mouse CD16/CD32
(eBioscience, catalog reference 16-0161-86) for 20 min at 4
°C, before membrane staining. Dead cells were excluded
using the Live/Dead Fixable Yellow dead cell stain kit (Life
Technologies). For cell phenotyping, the following antibodies
were purchased from BD Pharmingen: anti-mouse mouse
CD45 (catalog reference: 560510), anti-mouse CXCR5
(catalog reference: 551960), and anti-mouse CD3e (catalog
reference: 552774). The following antibodies were purchased
from BioLegend: anti-mouse CD4 (catalog reference:
100428), anti-mouse CXCR3 (catalog reference: 126531).
The following antibodies were purchased from R&D systems:
anti-mouse CCR6 (catalog reference: FAB590P). The fol-
lowing antibody was purchased from Invitrogen: anti-mouse
PD-1 (catalog reference: 17-9985-82). Samples were acquired
on 13-color Cytoflex (Beckman Coulter) and analyses were
performed with FlowJo v10 software (Tree Star, Ashland,
OR, USA).
External data availability of 16S RNA seq
Microbiota characterization was already reported [5]. All raw
sequencing data can be found at the NCBI Sequence Read
Archive (accession number: PRJNA478491; “Ileal Apoptosis
and Microbiome Shape Immunosurveillance and Prognosis of




The Mann–Whitney U test was used in comparisons of two
group parameters, after Kruskal–Wallis test for multiple
groups. The false-discovery rate was tested by the
Benjamini–Hochberg procedure [39]. Survival curves were
estimated using the Kaplan–Meier product limit method.
Association between variables and outcome was evaluated
using the log-rank test. Hierarchical clustering has been
done with the distance 1-Pearson correlation coefficient and
Ward’s agglomeration method. Statistics and graphics were
performed using the R software and GraphPad Prism v7.03.
All tests were two-sided, with mean ± SEM depicted, and
P values < 0.05 were considered statistically significant.
For human sample studies, the investigators were blinded
to group allocation during data collection and analysis. For
mice experiments, the investigators were not blinded to
group allocation when performing treatments during the
experiment, but they were blinded during data collection of
outcome and analysis.
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